Regional convection-enhanced delivery of gadolinium-labeled albumin in the rat hippocampus in vivo.
Convection-enhanced delivery (CED) has emerged as a promising method of targeted drug delivery for treating central nervous system (CNS) disorders, but the influence of brain structure on infusate distribution is unclear. We have utilized this approach to study extracellular transport and distribution of a contrast agent in the hippocampus, a complex structure susceptible to CNS disorders. The magnetic resonance (MR) contrast agent diethylene triamene penta-acetic acid chelated gadolinium-labeled albumin (Gd-albumin), tagged with Evans blue dye, was directly infused (V(i)=5 microl) into the dorsal and ventral hippocampus of seven male Sprague-Dawley rats. The final distribution profile of the contrast agent, a product of CED and limited diffusion, was observed in vivo using high-resolution T1-weighted MR imaging at 11.1T. Dense cell layers, such as the granule cell layer of the dentate gyrus and the pyramidal cell layer of CA1, appeared to be barriers to transport of the tracer. Three-dimensional distribution shape and volume (V(d)) differences, between the dorsal and ventral hippocampus infusions, were determined from the MR images using a semi-automatic segmentation routine (dorsal V(d)=23.4+/-1.8 microl, ventral V(d)=36.4+/-5.1 microl). Finer structural detail of the hippocampus was obtained using a combination of histological analysis and fluorescence imaging. This study demonstrates that CED has the potential to target all regions of the hippocampus and that tracer distribution is influenced by infusion site, underlying structure and circuitry, and extent of backflow. Therefore, CED, combined with high-resolution MR imaging, may be a useful strategy for delivering therapeutics for the treatment of CNS disorders affecting the hippocampus.
Astary
Garrett W
GW
Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.
Kantorovich
Svetlana
S
Carney
Paul R
PR
Mareci
Thomas H
TH
Sarntinoranont
Malisa
M
D000418:Albumins / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000818:Animals; D056547:CA1 Region, Hippocampal / Q000187:drug effects; D003287:Contrast Media; D018891:Dentate Gyrus / Q000187:drug effects; D046169:Dermoscopy; D004058:Diffusion; D016503:Drug Delivery Systems / Q000379:methods*; D005453:Fluorescence; D019786:Gadolinium DTPA / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006624:Hippocampus / Q000187:drug effects; D021621:Imaging, Three-Dimensional / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D009474:Neurons / Q000187:drug effects; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives; D017966:Pyramidal Cells / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley
D000418:Albumins; D003287:Contrast Media; C527235:Evans blue-DTPA-gadolinium; D009942:Organometallic Compounds; C058946:albumin-(gadolinium-DTPA); D004369:Pentetic Acid; D019786:Gadolinium DTPA